Among the pharmaceutical options available for treatment of ovarian cancer, attention has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies. Currently, single agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, and in association with pegylated liposomal doxorubicin for treatment of patients with relapsed partially platinum-sensitive ovarian cancer. This review aims at summarizing the available evidence about the clinical role of trabectedin in the management of patients with epithelial ovarian cancer. Novel perspectives coming from a better understanding of trabectedin mechanisms of action and definition of patients subgroups likely susceptible to benefit of trabectedin treatment are also presented.

Mascilini, F., Amadio, G., Di Stefano, M., Ludovisi, M., Di Legge, A., Conte, C., De Vincenzo, R. P., Ricci, C., Masciullo, V., Salutari, V., Scambia, G., Ferrandina, M. G., Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence, <<ONCOTARGETS AND THERAPY>>, 2014; 7 (N/A): 1273-1284. [doi:10.2147/OTT.S51550] [http://hdl.handle.net/10807/67120]

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

Mascilini, Floriana;Amadio, Giulia;Ludovisi, Manuela;Di Legge, Alessia;Conte, Carmine;De Vincenzo, Rosa Pasqualina;Ricci, Caterina;Masciullo, Valeria;Salutari, Vanda;Scambia, Giovanni;Ferrandina, Maria Gabriella
2014

Abstract

Among the pharmaceutical options available for treatment of ovarian cancer, attention has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mechanism of action and has been shown to be active in several human malignancies. Currently, single agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, and in association with pegylated liposomal doxorubicin for treatment of patients with relapsed partially platinum-sensitive ovarian cancer. This review aims at summarizing the available evidence about the clinical role of trabectedin in the management of patients with epithelial ovarian cancer. Novel perspectives coming from a better understanding of trabectedin mechanisms of action and definition of patients subgroups likely susceptible to benefit of trabectedin treatment are also presented.
Inglese
Mascilini, F., Amadio, G., Di Stefano, M., Ludovisi, M., Di Legge, A., Conte, C., De Vincenzo, R. P., Ricci, C., Masciullo, V., Salutari, V., Scambia, G., Ferrandina, M. G., Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence, <<ONCOTARGETS AND THERAPY>>, 2014; 7 (N/A): 1273-1284. [doi:10.2147/OTT.S51550] [http://hdl.handle.net/10807/67120]
File in questo prodotto:
File Dimensione Formato  
mascilini review.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.16 MB
Formato Adobe PDF
2.16 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/67120
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact